Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: )-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study. METHODS: -mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in the tyrosine kinase domain (cohort 1), those with tumors harboring a mutation in the tyrosine kinase domain previously treated with a HER2-directed antibody-drug conjugate (cohort 5), and those with tumors harboring a non-tyrosine kinase domain mutation (cohort 3). In cohort 1, patients were initially randomly assigned to receive zongertinib at a dose of 120 mg or 240 mg once daily. Patients in cohorts 5 and 3 initially received 240 mg daily. After an interim analysis of data from cohort 1, subsequently recruited patients across all cohorts received zongertinib at a dose of 120 mg. The primary end point was an objective response assessed by blinded independent central review (cohorts 1 and 5) or by investigator review (cohort 3). Secondary end points included the duration of response and progression-free survival. RESULTS: In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0.001 against a ≤30% benchmark) had a confirmed objective response; the median duration of response was 14.1 months (95% CI, 6.9 to not evaluable), and the median progression-free survival was 12.4 months (95% CI, 8.2 to not evaluable). Grade 3 or higher drug-related adverse events occurred in 13 patients (17%). In cohort 5 (31 patients), 48% of the patients (95% CI, 32 to 65) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 1 patient (3%). In cohort 3 (20 patients), 30% of the patients (95% CI, 15 to 52) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 5 patients (25%). Across all three cohorts, no cases of drug-related interstitial lung disease occurred. CONCLUSIONS: -mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Self-citationNon–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
Self-citationRobichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Self-citationZhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 205
Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 196
Self-citationLe, X., Cornelissen, R., Garassino, M., Clarke, J. M., Tchekmedyian, N., Goldman, J. W., Leu, S.-Y., Bhat, G., Lebel, F., Heymach, J. V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01323 · Cited by 160
Self-citationMechanisms of Resistance to Antibody-Drug Conjugates
Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., & Lecesne, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119674 · Cited by 159
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Gibbons, D. L., Fossella, F. V., Lam, V. K. L., Patel, A. B., Negrao, M. V., Le, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01113 · Cited by 109
Self-citation
Cited by
Items 101–153 of 153
Küçük, N., & Baskin, V. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01615-1
Metastasiertes nichtkleinzelliges Lungenkarzinom mit Treiberalterationen
Frille, A. (2026) · Zeitschrift für Pneumologie · doi:10.1007/s10405-026-00673-9
Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges
Frey, C. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100010
Nagasaka, M., Arter, Z., Park, C. H., Sarkari, A., & Ou, S. I. (2026) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s600499
Reinhorn, D. J., Kuten, J., Preeshagul, I. R., Eng, J., Ng, K., Drilon, A., Chaft, J. E., Santini, F. C., & Awad, M. M. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101024
“28,29 Therefore, TKIs might offer superior efficacy post-T-DXd compared with T-DM1.”
Practice‐Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025
Zhou, Z., Gao, W., Li, M. S. C., & Zhou, Q. (2026) · Cancer Innovation · doi:10.1002/cai2.70064
Zongertinib in Previously Treated HER2-Mutant NSCLC: Diarrhea Characterization and Management
EMJ (2026) · Oncology The American Medical Journal · doi:10.33590/oncolamj/095jfc59
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power
Subbiah, V., Dietrich, M., & Le, X. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01214-3
“Tyrosine kinases appear to be the most effective and tolerable group of agents directed at HER2 -mutated non-small cell lung cancer [24].”
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report
Koba, H., Tambo, Y., Murase, Y., Yoh, K., Izumi, H., Nishiyama, A., Sone, T., Shimizu, T., Nomura, S., Ueda, T., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109492
Self-citation(18461), Y. L., Li, D., Wu, L., Li, X., Fan, Y., Zhang, M., Guo, J., Yao, Y., Fang, J., Tang, K.-J., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.06.003
Chen, M., Gandhib, J., Wu, S., & Cheng, H. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2691245
“In cohort 3 of Beamion Lung-1 (20 previously treated patients with non-TKD mutations) the confirmed ORR was 30% (95% CI, 15–52), and grade ≥3 drug-related adverse events occurred in 25% [10].”
InfluentialScudamore, O., Wind, S., Grempler, R., Esmaeili, H., & Müller, F. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70182
“Zongertinib is an orally administered, irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing wild-type epidermal growth factor receptor (EGFR), thereby minimizing associated toxicities [6, 7].”
Elantably, D., Meerzaman, I., Hou, A. Y., Abdelhakeem, A., & Lou, Y. (2026) · Cancers · doi:10.3390/cancers18132121
“…SqCLC represent an important therapeutic gap as currently FDA-approved HER2-selective tyrosine kinase inhibitors (TKIs), including zogertinib and sevabertinib, were developed primarily for TKD-mutant non-squamous NSCLC and have showed limited and inconsistent activity in non-TKD mutations [33,34].”
InfluentialWang, Y.-Z., Wang, Y.-G., Pan, Y., Gang, X., Yan, J., Wang, X., Tang, H.-L., Li, H.-M., & Zhao, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218703
Smilnak, G., Singh, R., Dougherty, S. C., Maheshwari, S., Smith, V. L., Stelow, E. B., Kundu, D., Jin, R., Hall, R. D., & Gentzler, R. D. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.06.012
Din, S. M. U., Kiamos, A., Ali, S., Mehta, M. M., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146251
“The impressive results of this study led to accelerated FDA approval of zongertinib in 2025 and its listing as a first-line treatment option in NCCN guidelines for HER2 (ERBB2)-mutated advanced-stage NSCLC; however, phase III trials are still ongoing [75].”
InfluentialZullo, L., & Remón, J. (2026) · Cancers · doi:10.3390/cancers18142334
“The global, multicohort phase I Beamion LUNG-1 trial investigated zongertinib in HER2 -altered advanced or metastatic solid tumors in the phase Ia and in advanced or metastatic HER2 - mutant NSCLC in the phase Ib [96].”
InfluentialNassar, A. H., Halawi, J., & Herbst, R. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000834
Medical Management of Non–Small Cell Lung Cancer Brain Metastases in the Modern Era
Lu, B. Y., & Goldberg, S. B. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000840
Management of brain metastases in older adults with non–small cell lung cancer
Lopes, J. B., Schep, D. G., Sahgal, A., Rodrigues, R. F., & Menjak, I. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1858724
“(141, 142).”
HER2 mutation–derived neoantigens in NSCLC as actionable targets for TCR therapyPreprint
Montoya, A., Nie, H., Jiang, P., Slone, J. K., Shulga, Y. V., Patel, A., Menon, P. S., Polic, I., Bontekoe, E., Hong, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741830
Self-citationLi, X., Qi, K., Ou, S. I., & Hu, Y. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103943
Yang, Y., Jiang, W., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Lei, S., Wei, F., Tian, L., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109589
Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report
Torres-Jiménez, J., Serrano‐Gómez, C., Baena, J., Bote, H., Zurera-Berjaga, M., Martín, A. L., Ponce-Aix, S., Paz-Ares, L. G., & Zugazagoitia, J. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.08.010
Self-citationAntibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges
Paliogiannis, P., Fara, G., Zinellu, A., Fois, A. G., & Palmieri, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090868
“Whether ADCs should be administered sequentially, combined with targeted therapies, or reserved for specific resistance settings remains an important clinical question that will require prospective randomized evaluation [165,166].”
Naka, G. (2026) · Journal of Nihon University Medical Association · doi:10.4264/numa.85.4_159
Samart, P., Chanthateyanonth, S., Rodboon, N., Charoenvitayavorakul, N., Yamada, T., Yokoya, M., Chanvorachote, P., Issaragrisil, S., & Luanpitpong, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119898
Tkacheva, D. D., Laktionov, K., Kazakov, A. M., Kruteleva, S. Y., & Ishchanov, D. G. (2026) · Practical oncology · doi:10.31917/2702231
Touhami, S. K. (2026) · Libyan Medical Journal · doi:10.69667/lmj.26905
Hierarchical Composite Endpoints for Dose Optimization in Early Phase Oncology Trials
Wu, Y., Guo, X., Li, R., & Corre, C. L. (2026) · Pharmaceutical Statistics · doi:10.1002/pst.70123
Self-citationNext-generation tumor-agnostic targets on the horizon
Coleman, N., Liu, J., Beal, J. R., & Subbiah, V. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.08.009
Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review
Arrieta, O. G., Caballé‐Perez, E., Cabrera-Miranda, L. A., Cardona, A. F., Davila-Dupont, D., Velasco-Córdoba, M., & Treviño, L. A. C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105619
Yamashita, M., Ninomiya, K., Tomida, S., Nakata, E., Morita, A., Hara, N., Takada, K., Makimoto, G., Kubo, T., Ichihara, E., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117443
Lewis-Mikhael, A.-M., Wang, X., Bernard-Gauthier, V., Papadakis, K., Regales, L., Paracha, N., & Manevy, F. (2026) · Cancers · doi:10.3390/cancers18223640
Li, M. S. C., Soon, Y. Y., Au-Yeung, P. Y., Chan, A. L. S., Lee, J.-B., Nützinger, J., Tateishi, A., & Ross, S. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.106129
Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
Rabinovich, E. P., & Martin, L. W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197644
“Zongertinib demonstrated substantial activity in previously treated advanced HER2 TK domain-mutated NSCLC, with an objective response rate of 71% and median progression-free survival of 12.4 months, and received FDA accelerated approval for that setting in 2025 [38].”
InfluentialOba, T., Shiohira, S., Machida, Y., Nakatani, D., Akasaka, K., Amano, M., & Matsushima, H. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2026-0856
Yoshimura, A., Yoshida, J., Takumi, C., & Takayama, K. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01263-8
Review of 2025 approved small-molecule drugs by China NMPA: A new milestone
Hu, Y., He, F., He, C., Cao, C., Zhong, N., Yang, Z., & Li, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.015
Xu-Vuillard, A., Robert, A., Pistilli, B., Delaloge, S., Zeghondy, J., Bousrih, C., Sabău, A., Mosele, F., Viansone, A. A., Rassy, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11053506/v1
Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression
Piazza, F., Sharma, R., Esposito, A., Siniscalchi, C., Sacco, M., Moscvin, M., Wu, S., Sangaletti, S., Rizvi, N., Behera, V., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103235
Pan-Gynecologic Cancer Analysis of ERBB2 Gene Mutations Across More Than 21,000 Tumor Samples
Ahsan, M. D., Gysler, S. M., Ko, E., Guintoli, R. L., Kim, S. H., Latif, N., & Nasioudis, D. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105679
Zhang, T., Tan, C., Sun, H., Gu, W., Wang, W., Xu, M., & Sheng, W. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00850-9
Le, X., CHOUAID, C., López‐Ríos, F., Duh, M. S., DerSarkissian, M., Bernard-Gauthier, V., Zong, J., Vassilev, Z. P., Lunacsek, O., Lax, A., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109677
Kim, S. H., Jain, S., Shim, J. S. G., Cho, B. C., & Lim, S. M. (2026) · Yonsei Medical Journal · doi:10.3349/ymj.2026.0203
Self-citationWang, J., Xu, S., Hosseinikhah, S. M., Zhang, W., Zhang, X., & Sacchetti, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219938
Xia, X., Liu, L., & Du, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1998200
Kawanaka, Y., Yonesaka, K., Kuwahara, K., Dohi, W., Kurosaki, T., Suzuki, S., Murata, D., Kanemura, H., Watanabe, S., Takahama, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10782728/v1
Popat, S., Zugazagoitia, J., Planchard, D., Yamamoto, N., Yoh, K., Ruiter, G., Smit, E. F., Heymach, J. V., Tu, H.-Y., & Wu, Y.-L. L. C. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.11.002
Self-citationProtein Kinases in Cancer: From Carcinogenesis to Therapy and Resistance
Feng, J., Wang, Z., & Cui, Y.-Y. (2026) · Biology · doi:10.3390/biology15222058
The expansion of kinase drug discovery: new targets, platforms and indications
Sokolov, A. V., Fabbro, D., Knapp, S., & Schiöth, H. B. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01551-y
Friederike, D., Gorgulho, J., Jan, W., Alexander, S., & Joseph, T. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109144
Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors
Reddy, K. G., & Metya, A. K. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c03843
Metadata
- Authors
- Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H.-Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., & Zugazagoitia, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- The Netherlands Cancer Institute (NL)
- Samsung Medical Center (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Leiden University Medical Center (NL)
- Université Paris-Saclay (FR)
- Guangdong Academy of Medical Sciences (CN)
- Yonsei University (KR)
- National Cancer Center Hospital (JP)
- NYU Langone Health (US)
- Zhengzhou University (CN)
- National Cancer Center Hospital East (JP)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim Pharma, Biberach an der Riss, Germany
- Hospital Universitario 12 De Octubre (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-19
- Volume
- 392
- Issue
- 23
- Pages
- 2321-2333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409870405
- Semantic Scholar
- a2f803e8a004efcfe20ec66609ef88935fb403da
- Cited by
- 118
- References
- 25
- Citations by year
- 2026: 84 · 2025: 34
- FWCI
- 77.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (publishedVersion)
- HAL (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- zongertinib, HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, previously treated patients, tyrosine kinase domain mutations, objective response rate, progression-free survival, duration of response, drug-related adverse events, oral tyrosine kinase inhibitor
- MeSH terms
- Trastuzumab, Progression-Free Survival, Tyrosine Kinase Inhibitors, Adult, Aged, Aged, 80 and over, Camptothecin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.